Endocannabinoid System in Polycystic Kidney Disease

Area of Science:

• Nephrology
• Endocrinology
• Immunology

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder causing renal cysts and interstitial inflammation.
• The kidney expresses the endocannabinoid (EC) system, which plays a role in inflammation and kidney disease progression.

Purpose of the Study:

• To investigate endocannabinoid (EC) levels in patients with ADPKD.
• To explore the association between EC levels and disease progression in ADPKD.

Main Methods:

• A validated mass spectrometry assay was used to measure EC levels in 102 ADPKD patients and 100 healthy controls.
• Blood samples were collected at baseline and after 2 and 4 years, with patients on standard or rigorous blood pressure control.

Main Results:

• ADPKD patients exhibited higher interleukins-6 and -1b, and lower plasma levels of anandamide (AEA), 2-arachidonoyl-glycerol (2-AG), and related compounds compared to controls.
• Lower baseline AEA levels correlated with greater ADPKD progression (increased kidney volume) and poorer renal function (decreased eGFR).
• Palmitoylethanolamide (PEA) levels positively correlated with renal function improvement (eGFR change).

Conclusions:

• ADPKD is associated with reduced levels of key endocannabinoids (ECs).
• Augmenting AEA, PEA, and 2-AG levels, by enhancing synthesis or reducing degradation, could be a potential therapeutic approach for ADPKD.
• Targeting the renal EC system presents a promising avenue for ADPKD treatment.